Patents by Inventor Rosy S. Donn

Rosy S. Donn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained release intraocular implants and methods for preventing retinal dysfunction
    Patent number: 8609144
    Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: December 17, 2013
    Assignee: Allergan, Inc.
    Inventors: James Burke, Patrick M. Hughes, Orilla C. Werhner, Ton C. Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry A. Wheeler, Rosy S. Donn
  • Intraocular implants and methods for improving vision
    Patent number: 8293741
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: October 23, 2012
    Assignee: Allergan, Inc.
    Inventors: James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Glenn Huang, Brittany A. Jackson, Larry A. Wheeler, Rosy S. Donn
  • SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION
    Publication number: 20080299178
    Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.
    Type: Application
    Filed: June 19, 2008
    Publication date: December 4, 2008
    Applicant: ALLERGAN, INC.
    Inventors: James Burke, Patrick M. Hughes, Orilla C. Werhner, Ton Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry A. Wheeler, Rosy S. Donn
  • SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION
    Publication number: 20080260832
    Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.
    Type: Application
    Filed: June 19, 2008
    Publication date: October 23, 2008
    Applicant: ALLERGAN, INC.
    Inventors: James Burke, Patrick M. Hughes, Orilla C. Werhner, Ton Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry A. Wheeler, Rosy S. Donn